US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
AMEX
Ellomay Capital Ltd (ELLO)
Ellomay Capital Ltd (ELLO) ニュース

Ellomay Capital Ltd (ELLO)

21.30

-1.04

(-4.66%)

終了 6月6日 5:00AM

21.70

0.40

(1.88%)

取引時間後: 8:59AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital Reports Results for the Three Months Ended March 31, 2026

TEL-AVIV, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital Consummates the Sale of its Indirect Holdings in Dorad Energy Ltd.

Final Purchase Price is NIS 559.8 Million Tel-Aviv, Israel, May 10, 2026 (GLOBE NEWSWIRE) -- Ellomay...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital Announces the Filing of the Annual Report on Form 20-F for 2025

Tel-Aviv, Israel, , May 01, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2025

TEL AVIV, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

TEL-AVIV, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ellomay Capital to Sell its Indirect Holdings in Dorad Energy Ltd. based on a Dorad Valuation of NIS 4.4 Billion

Tel-Aviv, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

US Market News

US Market News 6分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 6分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 8分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 11分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 15分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 15分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 15分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 19分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 19分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 20分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 21分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 22分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 23分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 24分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 24分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 24分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 25分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 25分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 26分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 28分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 31分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Ellomay Capital

Xtrackers IE Public

iShares ESG Aware MSCI U...

Logan Energy (PK)

Flexshares Esg & Climate...

BMO Global Communication...

Nuveen ESG Dividend

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。